 Shares of Antares Pharma Inc. ATRS, -0.27 rocketed 46.3 in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics Inc. HALO, 0.58 in a cash deal valued at 960 million. Halozymes stock was still inactive ahead of the open. 